Alzheimer’s Association Business Consortium (AABC)

The mission of the Alzheimer’s Association Business Consortium (AABC) is to advance Alzheimer’s disease and dementia research through innovation in small- and medium-size biotechnology, diagnostics, medical device and contract research organizations.

AABC members work in areas of common interest pre-competitively to advance both the field of dementia research and the goals of its member organizations. They provide leadership and direction to the group’s areas of focus, which include, but are not limited to, collaborations, recognition and visibility, and knowledge and information sharing.

Collaborations

Collaborations are essential to companies as a way to share resources, expand infrastructure, save money and potentially create income. The consortium will provide a platform for companies looking for collaboration opportunities between member companies and enhance collaborations with large companies and other institutions external to the consortium.

Recognition and visibility

Companies will benefit from publications and positive publicity. As such, the AABC will look for ways to bring companies in this sector to the attention of the Alzheimer's Disease and Related Dementias community through publications, presentations and posters.

Knowledge and information sharing

The AABC will look for ways to share knowledge and information in a pre-competitive space. The group will share information about each member company. They may also share information on trusted consultants, CRO’s, ways to manage data in a small company, funding strategies and funding sources.

Consortium members

AI

Beacon Biosignals
BrainKey
Clarity
Cognetivity Neurosciences
DemAi Technologies
ForesightCares
HAII
Icometrix
Imeka
Innolyzer
Innovation Precision Health
Kernel
Mont4
NeuraMetrix
Neurotrack
Neuroworx
Novoic
QMENTA
Unlearn.AI
TELL
Vistim Labs
Wherible

Diagnostics

Alzeca Biosciences
ASDERA
Baseline Bioscience
Brain Spec
CarThera
CLAIRIgene
Cogni.Dx
Darmiyan
Esya Labs
Firalis Molecular Precision 
Imaginostics
InterVivo Solutions​
Keystone Bio
Oasis Diagnostics
Perceiv AI
Septa Therapeutics
Telocyte

Therapeutics

712 North
Acelot
Alpha Cognition
Asha
Cenna Biosciences
Cerecin
Cognition Therapeutics
Corvidane
Cyclerion
DiamiR
EpicentRx
ImmunoBrain Checkpoint
INmune Bio Inc.
Lauren Sciences
Manzanita Pharmaceuticals
Medesis Pharma
Mitochon Pharmaceuticals
NeuroScios
Progenicyte Therapeutics
Reservoir Neuro
Treventis

Other

Bioexpert
Neuronascent

 

Meeting agendas and meeting minutes

AABC webinars

Federal Grant Funding - March 2023 (VIDEO - please use passcode: e@MgG0h%)
Federal Grant Funding - March 2023 (PDF)
Leveraging SBIR/STTR to Advance Alzheimer’s and Aging Innovations (VIDEO)
Leveraging SBIR/STTR to Advance Alzheimer’s and Aging Innovations (PDF)
Updates in Neuroimaging - December 2019 (PDF)
Ask the Expert: CEO Panel - April 2019 (VIDEO)
NIA-AA Research Framework: Towards a Biological Definition of Alzheimer’s Disease - November 2018 (PDF)
Ask the Expert - August 2018 (PPT)
IR and PR Strategy for Emerging Alzheimer's Companies - June 2018 (PDF)
Ask The Expert - December 2017 (PDF)
Ask The Expert - September 2017 (PPT)
Ask The Expert - June 2017 (PPT)
Ask The Expert - April 2017 (PPT)
SBIR/STTR funding for Alzheimer's disease (PDF)
What does pharma look for in evaluating companies as potential partners? (PDF)

AABC / ISTAART webinars

May 2018
National Institute on Aging Small Business Award Program
 
October 2017
Biotech Innovation in New Therapeutic Approaches to Alzheimer's Disease

May 2017
Araclon ISTAART
Cytox Intro
DiamiR ISTAART
NanoSomiX ISTAART

Newsletters

The AABC newsletter welcomes new members to the Alzheimer's Association Business Consortium, shares pre-competitive news about clinical developments and lists upcoming events of interest to Alzheimer's disease researchers and to biotechnology, diagnostics, medical device companies and other organizations developing Alzheimer's treatments.

Quarter 1 2023 newsletter
Quarter 3 2023 newsletter
Quarter 3 2022 newsletter
Quarter 1 2022 newsletter
Quarter 3 2021 newsletter

Quarter 2 2021 newsletter
Quarter 1 2021 newsletter
Quarter 4 2020 newsletter
Quarter 3 2020 newsletter
Quarter 4 2019 newsletter
Quarter 3 2019 newsletter
Quarter 2 2019 newsletter
Quarter 1 2019 newsletter
Quarter 1 and 2 2018 newsletter
Quarter 3 2018 newsletter
Quarter 3 2017 newsletter
Quarter 2 2017 newsletter
Quarter 4 2017 newsletter
Quarter 3 2016 newsletter
Quarter 2 2016 newsletter
Quarter 4 2015 newsletter

Publications

Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank, Alzheimer’s Dementia: Translational Research & Clinical Interventions (TRCI) 

Maximizing the Potential of Small Companies in Alzheimer’s Disease Research: Challenges and Opportunities (PPT)

Events

Past events:
The AABC Translation Animal Models Group, chaired by Joseph Araujo, InterVivo Solutions, and facilitated by Rebecca Edelmayer, Alzheimer’s Association, in collaboration with MODEL-AD members held a think tank in Washington, D.C., Nov. 28-29, 2018. The think tank was a shoulder meeting to the Alzheimer’s Association Research Roundtable and was well attended. The agenda consisted of sessions addressing proteomics, genomics and metabolomics, modern behavioral models, and translational, experimental and operational issues. The think tank proceedings will be submitted for publication. View the guest logistics or agenda for more information.

Get more information

The AABC welcomes new members who are aligned in its commitment to research and innovation. To express interest in joining, email Dr. Codi Gharagouzloo, co-chair; Dr. Jake Donoghue, co-chair; or Christopher Weber, Ph.D., facilitator. 

For more information on the AABC, contact:

Christopher Weber, Ph.D.
Director, Global Science Initiatives
Medical & Scientific Relations
Alzheimer's Association
cweber@alz.org